Animal model for tendinopathy

Luo, Junchao; Wang, Zetao; Tang, Chaoying; Yin, Zi; Huang, Jian‐Pei; Ruan, Dengfeng; Yang, Fei; Wang, Canlong; Mo, Xianan; Li, Jiajin; Zhang, Jun; Fang, Cheng; Li, Jianyou; Chen, Xiao; Shen, Wei

doi:10.1016/j.jot.2023.06.005

Cited by 6 publications

(6 citation statements)

References 196 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present work, we introduced, for the first time, a combination of collagenase and a thermo-responsive hydrogel, specifically Pluronic F127, to generate a model of patellar tendinopathy. Type I collagenase was selected as the collagenolytic agent [91] for inducing the degeneration of the tendon tissue to produce tendon injury, a method that was previously employed in established models replicating this pathology [54][55][56][58][59][60][61]. Pluronic F127 hydrogel was chosen for its documented properties as a thermo-responsive, non-toxic, biodegradable, and FDA-approved hydrogel [69,70].…”

Section: Discussionmentioning

confidence: 99%

“…Different types of enzymes can degrade the collagen matrix, but the most commonly used enzyme for generating tendinopathy models is collagenase type I, although there is no established consensus regarding the concentration and volume of collagenase to be injected [58]. De Cesar Netto et al tested different doses and serial injections of collagenase for the development of an Achilles tendinopathy model in rabbits [59].…”

Section: Of 23mentioning

confidence: 99%

See 1 more Smart Citation

A Novel Tendon Injury Model, Induced by Collagenase Administration Combined with a Thermo-Responsive Hydrogel in Rats, Reproduces the Pathogenesis of Human Degenerative Tendinopathy

Vidal,

Lopez-Garzon,

Venegas

et al. 2024

IJMS

View full text Add to dashboard Cite

Patellar tendinopathy is a common clinical problem, but its underlying pathophysiology remains poorly understood, primarily due to the absence of a representative experimental model. The most widely used method to generate such a model is collagenase injection, although this method possesses limitations. We developed an optimized rat model of patellar tendinopathy via the ultrasound-guided injection of collagenase mixed with a thermo-responsive Pluronic hydrogel into the patellar tendon of sixty male Wistar rats. All analyses were carried out at 3, 7, 14, 30, and 60 days post-injury. We confirmed that our rat model reproduced the pathophysiology observed in human patients through analyses of ultrasonography, histology, immunofluorescence, and biomechanical parameters. Tendons that were injured by the injection of the collagenase–Pluronic mixture exhibited a significant increase in the cross-sectional area (p < 0.01), a high degree of tissue disorganization and hypercellularity, significantly strong neovascularization (p < 0.01), important changes in the levels of types I and III collagen expression, and the organization and presence of intra-tendinous calcifications. Decreases in the maximum rupture force and stiffness were also observed. These results demonstrate that our model replicates the key features observed in human patellar tendinopathy. Collagenase is evenly distributed, as the Pluronic hydrogel prevents its leakage and thus, damage to surrounding tissues. Therefore, this model is valuable for testing new treatments for patellar tendinopathy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Of 23mentioning

confidence: 99%

A Novel Tendon Injury Model, Induced by Collagenase Administration Combined with a Thermo-Responsive Hydrogel in Rats, Reproduces the Pathogenesis of Human Degenerative Tendinopathy

Vidal,

Lopez-Garzon,

Venegas

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

“…Collagenase injection therefore induces tissue alterations that are closely coordinated with the pathophysiological modifications seen in human tendinopathy, extending beyond simple tendinitis characterized by inflammatory infiltration. For these reasons, it is also one of the most commonly used approach for modeling tendinopathy in animals [ 64 ]. Perhaps one of the most important functions of TSCs driving tendon repair in this study is their ability to inhibit neovascularization, which is now recognized as an early-stage indicator of pathological transformation in tendinopathy.…”

Section: Discussionmentioning

confidence: 99%

Tissue-engineered mesenchymal stem cell constructs alleviate tendinopathy by suppressing vascularization

Li,

Jiu,

Liu

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

“…Most of them reported improvements in the tendon structure and composition [12][13][14][15], but this could not be convincingly confirmed in other experimental studies [16,17]. The conflicting outcomes of experimental studies could be due to different models for tendon lesion induction used (collagenase injection vs. mechanical disruption), while no model can actually reflect the complex naturally occurring pathophysiology [18][19][20][21]. In this context, the study in horses with naturally occurring tendinopathy performed by Smith et al (2013) needs to be highlighted [22].…”

Section: Introductionmentioning

confidence: 97%

Treatment of Naturally Occurring Tendon Disease with Allogeneic Multipotent Mesenchymal Stromal Cells: A Randomized, Controlled, Triple-Blinded Pilot Study in Horses

Burk,

Wittenberg-Voges,

Schubert

et al. 2023

Cells

View full text Add to dashboard Cite

The treatment of tendinopathies with multipotent mesenchymal stromal cells (MSCs) is a promising option in equine and human medicine. However, conclusive clinical evidence is lacking. The purpose of this study was to gain insight into clinical treatment efficacy and to identify suitable outcome measures for larger clinical studies. Fifteen horses with early naturally occurring tendon disease were assigned to intralesional treatment with allogeneic adipose-derived MSCs suspended in serum or with serum alone through block randomization (dosage adapted to lesion size). Clinicians and horse owners remained blinded to the treatment during 12 months (seven horses per group) and 18 months (seven MSC-group and five control-group horses) of follow-up including clinical examinations and diagnostic imaging. Clinical inflammation, lameness, and ultrasonography scores improved more over time in the MSC group. The lameness score difference significantly improved in the MSC group compared with the control group after 6 months. In the MSC group, five out of the seven horses were free of re-injuries and back to training until 12 and 18 months. In the control group, three out of the seven horses were free of re-injuries until 12 months. These results suggest that MSCs are effective for the treatment of early-phase tendon disease and provide a basis for a larger controlled study.

show abstract

Animal model for tendinopathy

Cited by 6 publications

References 196 publications

A Novel Tendon Injury Model, Induced by Collagenase Administration Combined with a Thermo-Responsive Hydrogel in Rats, Reproduces the Pathogenesis of Human Degenerative Tendinopathy

A Novel Tendon Injury Model, Induced by Collagenase Administration Combined with a Thermo-Responsive Hydrogel in Rats, Reproduces the Pathogenesis of Human Degenerative Tendinopathy

Tissue-engineered mesenchymal stem cell constructs alleviate tendinopathy by suppressing vascularization

Treatment of Naturally Occurring Tendon Disease with Allogeneic Multipotent Mesenchymal Stromal Cells: A Randomized, Controlled, Triple-Blinded Pilot Study in Horses

Contact Info

Product

Resources

About